Long Term Omeprazole Side Effects When You Also Take Pain Pills

A fifty-eight-year-old man tracked every calorie for a month to prove to me he was not undereating. He was right. He had also swallowed omeprazole every morning since 2015, his stools had been loose for four years, and his colonoscopy was read as normal. If you live with chronic pain and a medicine cabinet that grew one refill at a time, the long term omeprazole side effects in his story are probably sitting in yours.

My video Full of Calories, Starving One Cell Deep covers the fuel his colon lining stopped receiving. Here is the pain patient’s half: what the acid blocker does to bacteria, what it does beside an anti-inflammatory, and what a pain practice should do about it.

Why the acid blocker and the pain pill share a cabinet

Fairness first. A proton pump inhibitor is the right drug for erosive esophagitis, for an ulcer that has to heal, and for a patient on daily anti-inflammatories whose stomach would otherwise bleed. Anti-inflammatories are legitimate pain medicine. Both buy time for a damaged surface, and time is not a small gift.

The failure is duration. The pair often starts during a flare, to protect the stomach while inflammation is treated. The flare resolves. The refills do not. No one decided you should be on both for a decade. The incentive decided: reviewing a prescription pays a clinic nothing, and renewing one pays for the visit. That is the same structural problem as two doctors managing one bowel with nobody in charge.

Long term omeprazole side effects begin in the bacteria

In 1,815 people across three cohorts, 211 of them taking a proton pump inhibitor, use came with significantly decreased diversity and changes in 20% of bacterial taxa. The organisms that rose were Enterococcus, Streptococcus, Staphylococcus and Escherichia coli, and the investigators read that as movement toward the state which precedes Clostridioides difficile infection. At population level, they wrote, the effect is more prominent than antibiotics.

A later analysis went wider. Across 1,883 stool samples, with 1,126 people taking at least one drug, 19 of 41 drug categories left a signal. Only one drug shifted the entire community in all three cohorts, and it was the acid blocker. Its single-drug signature covered 40 taxa and 166 microbial pathways; 24 taxa and 133 pathways survived correction for everything else being taken. Forty-six pathways were dose dependent, and people on 40 mg a day or more showed a marked drop in an amino acid pathway compared with low-dose users.

The investigators printed their own limits. Overall richness did not fall with any drug, and the design is cross-sectional, so confounding by indication cannot be excluded. Neither study measured butyrate. This is observational evidence of an ecosystem being reshaped, not proof of disease.

The drug that guards the stomach and injures the bowel below it

Here is the finding that should change the conversation in a pain clinic. Fifty-seven healthy volunteers took celecoxib 200 mg twice a day for two weeks, with either rabeprazole 20 mg or placebo. Small bowel injury appeared in 44.4% against 16.7%, a relative risk of 2.67.

The detail is sharper than the headline. Erosions were more common with the acid blocker added; ulcers were not. The injury had an address: 26% of the acid-blocker group developed damage in the jejunum and none of the placebo group did, with no such trend in the ileum. The authors cite a background rate of 60% to 80% small bowel injury in people taking older anti-inflammatories and acid blockers together.

Grade it honestly: capsule endoscopy, healthy young volunteers, two weeks, a selective anti-inflammatory, no bleeding or symptom endpoint. A surrogate, not an outcome. It is also the only randomized test of a combination millions of people take.

Why a starved colon matters to a nervous system in pain

The colon lining runs on butyrate, and no human cell makes it. Commensal bacteria build it out of the fiber we cannot digest, or it does not get built. That lining rebuilds itself about every three and a half days, pooled across 85 studies and 265 people, so the supply has to arrive daily.

What the fuel buys is not warmth. It is oxygen consumption. In mouse and cell work, butyrate raised epithelial oxygen use 4.6-fold and stabilized the hypoxia-inducible factor 11.8-fold, and that burning holds the surface below about 10 mmHg. Take the producers away and the cell stops burning fat, turns glucose into lactate, uses far less oxygen, and the remainder leaks into the lumen. A room built to hold no air gets some, and organisms that tolerate air move in.

Note the second requirement, because it describes our patients. Losing that signal alone was not sufficient to raise luminal oxygen; an inflammatory second hit was required. Two inputs, not one. This tier is mouse and cell biology, and the human version does not exist, because you cannot hold an oxygen probe against a living person’s epithelium for a week.

Now add the host a pain patient actually brings: visceral fat pumping out inflammatory signals, insulin running high, sleep broken most nights by the pain itself. The gut is the first brain, the organ in your skull is the second, and the vagus keeps them talking. A patient with an inflamed lining and a sensitized cord has two fires burning, and a procedure reaches one of them. That is why metaflammation gets treated as a target rather than a footnote, and why we ask what is in the cabinet before planning anything.

The trials that would have excluded you

Every study named here enrolled someone cleaner than the man in my office. The drug-pair trial used healthy young volunteers. The butyrate trials would have turned him away for the loose stools, or the omeprazole, or both. A trial isolates one disease to get a clean answer, and the complicated patient is what gets removed to get it. He is the patient I have.

What we changed first, and what it feels like

The plan was food and a review, not another prescription.

• Fiber, raised slowly, weighted toward psyllium. Across 16 trials and 1,251 adults with constipation, 66% responded to fiber against 41% on control, and the effect was carried by psyllium and pectin, above 10 g a day, at four weeks or longer.
• Expect gas, and plan for it. Flatulence worsened in those trials by more than stool consistency improved. Psyllium does not stop fermentation; it changes where and how fast the gas appears, which is why it blunts what inulin does. Bloating early on is expected physiology, not failure, and I say that before we start rather than after the phone call.
• A current reason for the acid blocker. Not whether to stop it, which is a decision for you and your physician, but what the original indication was, when it was last examined, and whether an anti-inflammatory is still going down with it.
• Pain control that does not lean on the pair. When an interventional procedure quiets the generator, the daily anti-inflammatory is often no longer doing the heavy lifting, and the acid blocker conversation gets much easier. Injections follow clinical need, never a calendar.

The physiology behind the food is a chain: fiber feeds the producers, the producers make butyrate, the lining burns it to keep its own surface airless, and an airless surface keeps the anaerobes that built it. Nobody has measured that chain end to end in a living person. I would rather call it mechanism than dress it up as proof.

For the man in the opening, it meant thirty grams of fiber a day reached gradually, and a planned taper of a prescription whose reason had last been examined in 2015. He had been starving his lining from both directions: nothing arriving that a bacterium could ferment, and a drug reshaping the fermenters. Both ends are yours to change. Every study here, with the numbers it does and does not support and the questions to bring your own physician, sits in the companion Deep Dive to the video. Next comes what industrial food additives do to the layer this fuel protects.

Frequently asked questions

Can omeprazole cause loose stools after years without trouble?

It can change the ecosystem that governs your stools. Use came with lower diversity and shifts in 20% of bacterial taxa, and the organisms that rose included Enterococcus and Escherichia coli. That is an association in cross-sectional human data, not a verdict on your case, and loose stools have other causes worth ruling out first. Bring the symptom and the prescription to one appointment. Split care is how a bowel problem goes unowned for years.

Is it safe to take an anti-inflammatory and an acid blocker together for years?

Both drugs have real indications, and the pairing is standard practice for stomach protection. The randomized evidence says that protection carries a price lower down: jejunal damage in 26% of volunteers given the pair, against none on placebo. Whether the trade suits you depends on your bleeding risk and your alternatives, which is a conversation for your prescriber. Anti-inflammatories carry systemic costs of their own.

Will a butyrate capsule fix a starved colon?

The delivery arithmetic is against it. Only 2% of butyrate arriving in the human colon gets into the blood, enema trials pooled across 227 patients showed nothing clinical, and the one strong oral trial was done in children with obesity. Fiber has the evidence a capsule does not, because this fuel is made on site by bacteria that need something to ferment. The blood supply behind that lining is a separate problem.

Why would a gut problem make my pain worse?

Because pain is not manufactured only where it hurts. A lining under inflammatory stress is one more input to a nervous system already running hot, and the insulin resistance and visceral inflammation that drive joint and nerve pain also shape the gut environment. We treat that terrain as part of the pain plan rather than as a side issue. High insulin has a pain mechanism of its own.

How much fiber, and how fast?

The randomized evidence in constipation sits above 10 g a day, sustained at least four weeks, and favors psyllium and pectin. Thirty grams a day is a reasonable target for someone eating almost nothing fermentable now, reached over weeks rather than days, because the gas is the fermentation starting up. If you have inflammatory bowel disease or a known stricture, that plan goes through your gastroenterologist first. When you eat is a separate lever.

Sources

1. Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J., Dijkstra, G., Franke, L., Xavier, R. J., Jonkers, D., Wijmenga, C., Weersma, R. K., & Zhernakova, A. (2016). Proton pump inhibitors affect the gut microbiome. Gut, 65(5), 740-8. https://doi.org/10.1136/gutjnl-2015-310376
2. Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., Mujagic, Z., Jonkers, D. M. A. E., Masclee, A. A. M., Fu, J., Kurilshikov, A., Wijmenga, C., Zhernakova, A., & Weersma, R. K. (2020). Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature communications, 11(1), 362. https://doi.org/10.1038/s41467-019-14177-z
3. Washio, E., Esaki, M., Maehata, Y., Miyazaki, M., Kobayashi, H., Ishikawa, H., Kitazono, T., & Matsumoto, T. (2016). Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: A randomized, placebo-controlled trial. Clinical gastroenterology and hepatology, 14(6), 809-815.e1. https://doi.org/10.1016/j.cgh.2015.10.022
4. Kelly, C. J., Zheng, L., Campbell, E. L., Saeedi, B., Scholz, C. C., Bayless, A. J., Wilson, K. E., Glover, L. E., Kominsky, D. J., Magnuson, A., Weir, T. L., Ehrentraut, S. F., Pickel, C., Kuhn, K. A., Lanis, J. M., Nguyen, V., Taylor, C. T., & Colgan, S. P. (2015). Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host & Microbe, 17(5), 662-671. https://doi.org/10.1016/j.chom.2015.03.005
5. Byndloss, M. X., Olsan, E. E., Rivera-Chávez, F., Tiffany, C. R., Cevallos, S. A., Lokken, K. L., Torres, T. P., Byndloss, A. J., Faber, F., Gao, Y., Litvak, Y., Lopez, C. A., Xu, G., Napoli, E., Giulivi, C., Tsolis, R. M., Revzin, A., Lebrilla, C. B., & Bäumler, A. J. (2017). Microbiota-activated PPAR-gamma signaling inhibits dysbiotic Enterobacteriaceae expansion. Science, 357(6351), 570-575. https://doi.org/10.1126/science.aam9949
6. van der Schoot, A., Drysdale, C., Whelan, K., & Dimidi, E. (2022). The effect of fiber supplementation on chronic constipation in adults: An updated systematic review and meta-analysis of randomized controlled trials. The American journal of clinical nutrition, 116(4), 953-969. https://doi.org/10.1093/ajcn/nqac184
7. Gunn, D., Abbas, Z., Harris, H. C., Major, G., Hoad, C., Gowland, P., Marciani, L., Gill, S. K., Warren, F. J., Rossi, M., Remes-Troche, J. M., Whelan, K., & Spiller, R. C. (2022). Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies. Gut, 71(5), 919-927. https://doi.org/10.1136/gutjnl-2021-324784
8. Jamka, M., Kokot, M., Kaczmarek, N., Bermagambetova, S., Nowak, J. K., & Walkowiak, J. (2021). The effect of sodium butyrate enemas compared with placebo on disease activity, endoscopic scores, and histological and inflammatory parameters in inflammatory bowel diseases: A systematic review of randomised controlled trials. Complementary medicine research, 28(4), 344-356. https://doi.org/10.1159/000512952
9. Darwich, A. S., Aslam, U., Ashcroft, D. M., & Rostami-Hodjegan, A. (2014). Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 42(12), 2016-2022. https://doi.org/10.1124/dmd.114.058404

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 14 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.

Dr. Gurpreet Singh Padda, MD, MBA, MHP